ZATTARIN, EMMA
 Distribuzione geografica
Continente #
EU - Europa 1.040
NA - Nord America 303
AS - Asia 298
SA - Sud America 45
AF - Africa 6
OC - Oceania 4
Totale 1.696
Nazione #
DE - Germania 735
US - Stati Uniti d'America 302
CN - Cina 102
IT - Italia 97
SG - Singapore 92
NL - Olanda 53
SE - Svezia 46
BR - Brasile 40
IN - India 29
RU - Federazione Russa 22
HK - Hong Kong 21
GB - Regno Unito 20
ID - Indonesia 18
IE - Irlanda 18
FR - Francia 17
VN - Vietnam 12
FI - Finlandia 10
JP - Giappone 8
AT - Austria 5
KR - Corea 4
CH - Svizzera 3
CZ - Repubblica Ceca 3
AU - Australia 2
BE - Belgio 2
BO - Bolivia 2
DK - Danimarca 2
EG - Egitto 2
IQ - Iraq 2
JO - Giordania 2
NZ - Nuova Zelanda 2
RO - Romania 2
TR - Turchia 2
UA - Ucraina 2
AZ - Azerbaigian 1
CA - Canada 1
DZ - Algeria 1
EC - Ecuador 1
ES - Italia 1
ET - Etiopia 1
IS - Islanda 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
PE - Perù 1
PH - Filippine 1
TM - Turkmenistan 1
TN - Tunisia 1
TW - Taiwan 1
VE - Venezuela 1
Totale 1.696
Città #
Frankfurt am Main 706
Chandler 74
Singapore 64
Ashburn 26
Santa Clara 25
Milan 24
Council Bluffs 18
Dublin 18
Bengaluru 13
Jakarta 12
Cangzhou 11
Hong Kong 10
Hyderabad 10
Nuremberg 10
Princeton 10
Beijing 9
Dong Ket 8
Helsinki 8
Phoenix 8
Southend 8
Rho 7
Shanghai 7
London 6
Wilmington 6
Düsseldorf 5
Salt Lake City 5
Chicago 4
Eitensheim 4
Ho Chi Minh City 4
Los Angeles 4
São Paulo 4
Voghera 4
Cagliari 3
Medford 3
Perugia 3
Quanzhou 3
Rome 3
Seoul 3
Tokyo 3
Turin 3
Zurich 3
Amman 2
Auckland 2
Berlin 2
Bernareggio 2
Brno 2
Brussels 2
Bucharest 2
Cairo 2
Cambridge 2
Casorate Primo 2
Fuzhou 2
Gioia del Colle 2
Juiz de Fora 2
Lauterbourg 2
Manchester 2
Menlo Park 2
Menteng 2
Monza 2
Munich 2
New York 2
Portsmouth 2
Reggio Calabria 2
Seattle 2
Shenzhen 2
Tampa 2
Taranto 2
Upper Marlboro 2
Vienna 2
Aarhus 1
Addis Ababa 1
Almaty 1
Altamura 1
Americana 1
Amsterdam 1
Ann Arbor 1
Armazém 1
Ashgabat 1
Baghdad 1
Baku 1
Ben Arous 1
Bernate Ticino 1
Blida 1
Brescia 1
Buffalo 1
Canaã dos Carajás 1
Canindé 1
Cariacica 1
Chongqing 1
Cologne 1
Colombo 1
Conceição do Jacuípe 1
Curitiba 1
Dallas 1
De Kwakel 1
Des Moines 1
Drexel Hill 1
Elk Grove Village 1
Erval Grande 1
Florence 1
Totale 1.246
Nome #
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin 143
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy 137
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology 131
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 126
Evaluation of drug-drug interactions in EGFR-mutated non-small-cell lung cancer patients during treatment with tyrosine-kinase inhibitors 117
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients 114
The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab 114
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) 109
Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study 105
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer 103
Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic 98
Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report 98
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications 96
Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)epositive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy 93
“Heterogeneity of treatment effect on patients’ long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.” 37
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis 28
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer 22
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors 15
Sarcopenia and monocyte-to-lymphocyte ratio as prognostic factors in early-stage breast cancer 13
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications 13
Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysis 12
Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications 11
Fasting-mimicking diet plus chemotherapy in breast cancer treatment 10
The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis 9
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis 5
null 3
Gender-Based Differences in the Efficacy of Anti-EGFR/BRAF/MEK Targeted Therapy in Patients with BRAF-Mutated Metastatic Colorectal Cancer 1
Abstract HER2-02: HER2-02 HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy 1
Totale 1.764
Categoria #
all - tutte 5.158
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.158


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 1 2 9
2021/202265 0 3 2 1 4 2 1 8 2 1 16 25
2022/2023247 23 25 18 18 24 45 5 23 32 4 29 1
2023/2024649 11 10 14 13 44 35 111 82 40 88 104 97
2024/2025791 84 99 92 96 50 30 55 65 67 124 29 0
Totale 1.764